Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
13445 | 772 | 33.8 | 72% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CD13 | Author keyword | 58 | 51% | 11% | 82 |
2 | AMINOPEPTIDASE N | Author keyword | 48 | 35% | 14% | 111 |
3 | UBENIMEX | Author keyword | 38 | 86% | 2% | 19 |
4 | AMINOPEPTIDASE N APN CD13 | Author keyword | 33 | 100% | 2% | 13 |
5 | APN CD13 | Author keyword | 31 | 92% | 2% | 12 |
6 | BESTATIN | Author keyword | 27 | 38% | 7% | 55 |
7 | NGR HTNF | Author keyword | 13 | 71% | 1% | 10 |
8 | AMINOPEPTIDASE N INHIBITORS | Author keyword | 11 | 100% | 1% | 6 |
9 | PROBESTIN | Author keyword | 11 | 100% | 1% | 6 |
10 | NGR PEPTIDE | Author keyword | 10 | 73% | 1% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CD13 | 58 | 51% | 11% | 82 | Search CD13 | Search CD13 |
2 | AMINOPEPTIDASE N | 48 | 35% | 14% | 111 | Search AMINOPEPTIDASE+N | Search AMINOPEPTIDASE+N |
3 | UBENIMEX | 38 | 86% | 2% | 19 | Search UBENIMEX | Search UBENIMEX |
4 | AMINOPEPTIDASE N APN CD13 | 33 | 100% | 2% | 13 | Search AMINOPEPTIDASE+N+APN+CD13 | Search AMINOPEPTIDASE+N+APN+CD13 |
5 | APN CD13 | 31 | 92% | 2% | 12 | Search APN+CD13 | Search APN+CD13 |
6 | BESTATIN | 27 | 38% | 7% | 55 | Search BESTATIN | Search BESTATIN |
7 | NGR HTNF | 13 | 71% | 1% | 10 | Search NGR+HTNF | Search NGR+HTNF |
8 | AMINOPEPTIDASE N INHIBITORS | 11 | 100% | 1% | 6 | Search AMINOPEPTIDASE+N+INHIBITORS | Search AMINOPEPTIDASE+N+INHIBITORS |
9 | PROBESTIN | 11 | 100% | 1% | 6 | Search PROBESTIN | Search PROBESTIN |
10 | NGR PEPTIDE | 10 | 73% | 1% | 8 | Search NGR+PEPTIDE | Search NGR+PEPTIDE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CD13 | 95 | 70% | 10% | 80 |
2 | N CD13 | 79 | 85% | 5% | 41 |
3 | CD13 APN | 42 | 94% | 2% | 15 |
4 | APN CD13 | 37 | 100% | 2% | 14 |
5 | UBENIMEX BESTATIN | 32 | 85% | 2% | 17 |
6 | UBENIMEX | 26 | 80% | 2% | 16 |
7 | BESTATIN | 25 | 25% | 11% | 85 |
8 | CD13 AMINOPEPTIDASE N | 19 | 70% | 2% | 16 |
9 | CD13 GP150 | 18 | 89% | 1% | 8 |
10 | EC 34112 | 17 | 100% | 1% | 8 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Aminopeptidase N (CD13) as a target for cancer chemotherapy | 2011 | 58 | 84 | 73% |
The moonlighting enzyme CD13: old and new functions to target | 2008 | 92 | 107 | 58% |
The neovasculature homing motif NGR: more than meets the eye | 2008 | 77 | 83 | 49% |
Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems | 2011 | 19 | 77 | 58% |
The structure and main functions of aminopeptidase N | 2007 | 71 | 18 | 61% |
Positioning of aminopeptidase inhibitors in next generation cancer therapy | 2014 | 7 | 103 | 33% |
Recent Advance in Aminopeptidase N (APN/CD13) Inhibitor Research | 2011 | 8 | 40 | 90% |
Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects | 2006 | 129 | 323 | 35% |
Aminopeptidase N (APN/CD13) as a Target for Anti-Cancer Agent Design | 2008 | 27 | 65 | 65% |
CD13 - not just a marker in leukemia typing | 1999 | 149 | 71 | 32% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | VASC BIOL MC3501 | 3 | 100% | 0.4% | 3 |
2 | PEGGY CHARLES STEPHENSON OKLAHOMA CANC | 2 | 44% | 0.5% | 4 |
3 | NANOTECHNOL DRUGS | 1 | 50% | 0.3% | 2 |
4 | BASURTO UNIV HOSP | 1 | 33% | 0.4% | 3 |
5 | NURSING 1 | 1 | 16% | 0.9% | 7 |
6 | EA4566 | 1 | 40% | 0.3% | 2 |
7 | INTERDISCIPLINARY CLIN IZKF MUENSTER | 1 | 40% | 0.3% | 2 |
8 | PRECLIN STUDY NEW TRADIT CHINESE MED GANS | 1 | 40% | 0.3% | 2 |
9 | ONCOL 5 | 1 | 18% | 0.6% | 5 |
10 | EXPT HAEMATOL IMMUNOL ONCOL | 1 | 27% | 0.4% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000174953 | DIPEPTIDYL PEPTIDASE III//GOAT BRAIN//PEPTIDASE FAMILY M49 |
2 | 0.0000174845 | PROLYL AMINOPEPTIDASE//TRIPEPTIDYL PEPTIDASE II//AMINOPEPTIDASE |
3 | 0.0000146531 | ANGIOTENSIN IV//AT4 RECEPTOR//AMINOPEPTIDASE A |
4 | 0.0000105098 | CD26//DIPEPTIDYL PEPTIDASE IV//SEPRASE |
5 | 0.0000093572 | NEUTRAL ENDOPEPTIDASE//OMAPATRILAT//VASOPEPTIDASE INHIBITOR |
6 | 0.0000054478 | SUCRASE ISOMALTASE//LACTASE PHLORHIZIN HYDROLASE//LACTASE PHLORIZIN HYDROLASE |
7 | 0.0000051055 | PHAGE DISPLAY//LANDSCAPE PHAGE//IN VIVO PHAGE DISPLAY |
8 | 0.0000050498 | BLEOMYCIN AMPLIFICATION//PHENYLACETATE//ANTINEOPLASTON AS2 1 |
9 | 0.0000041774 | PREUSSIN//HAPALOSIN//ALPHA AMINO ALDEHYDES |
10 | 0.0000040525 | PORCINE EPIDEMIC DIARRHEA VIRUS//PEDV//PORCINE EPIDEMIC DIARRHEA VIRUS PEDV |